I-Mab at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript

May 14, 2020 / 01:40PM GMT
Yang Huang - BofA Merrill Lynch, Research Division - Research Analyst

Hello, everyone. Thank you for coming and to join the call for I-Mab. I'm Bank of America analyst, Yang Huang, covering China health care. And today, we're inviting Dr. Zang Jingwu to give our -- a presentation to introduce the most recent update for I-Mab. As you know, I-Mab recently IPO-ed and has quite a few updates on its clinical pipeline.

And yes, so Dr. Zang, you can start.

Jingwu Zhang Zang - I-Mab - Founder, Honorary Chairman & Director

Pleased to introduce I-Mab biopharma. I-Mab biopharma is unique among China-based biotech companies as we only focus on discovery, development and the future commercialization of biologics, innovative biologics with first-in-class, best-in-class potential. This focus is mostly attributable to our R&D strengths in immunology, and we stand out as a leading immunology company in China.

If you turn to Page 2, we have been taking 2 strategies to build our pipeline. One strategy, I'll call it, global strategy, where we rely on

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
4.6 out of 5 Trustpilot